Nasopharyngeal Carcinoma clinical trials

Explore recruiting nasopharyngeal carcinoma clinical trials.

Recruiting nasopharyngeal carcinoma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Nasopharyngeal Carcinoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Nivolumab in combination with cisplatin and 5-fluorouracil as induction therapy in children and adults with EBV-positive nasopharyngeal carcinoma

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

Towards improved therapy selection and targeted treatment for nasopharyngeal carcinoma. A proof-of-concept pilot study for somatostatin receptor 2 imaging with [68Ga]Ga-DOTA-TOC PET/CT: the NACASOR trial

Netherlands

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Study of safety and efficacy of DKY709 alone or in combination with PDR001 in patients with advanced solid tumors.

Spain, Germany

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Phase II study evaluating the efficacy of Nivolumab in the treatment of patients with nasopharyngeal cancer who progressed during or after platinum-based chemotherapy

Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-A3055, Alone and in Combination With Tislelizumab in Patients With Selected Advanced or Metastatic Solid Tumors

France

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the DGKζ Inhibitor BGB-30813, Alone or in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab, in Patients With Advanced or Metastatic Solid Tumors

Spain

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Nasopharyngeal Carcinoma trials by city

Nasopharyngeal Carcinoma in Toronto Nasopharyngeal Carcinoma in Vancouver Nasopharyngeal Carcinoma in Montreal Nasopharyngeal Carcinoma in Calgary Nasopharyngeal Carcinoma in Edmonton Nasopharyngeal Carcinoma in Ottawa Nasopharyngeal Carcinoma in Winnipeg Nasopharyngeal Carcinoma in Quebec City Nasopharyngeal Carcinoma in Hamilton Nasopharyngeal Carcinoma in Kitchener Nasopharyngeal Carcinoma in London Nasopharyngeal Carcinoma in Halifax Nasopharyngeal Carcinoma in New York Nasopharyngeal Carcinoma in Los Angeles Nasopharyngeal Carcinoma in Chicago Nasopharyngeal Carcinoma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease